Board and management
Education and professional experience: Gösta holds a PhD in Cell-and Molecular Biology from Lund University. Former experience in the pharmaceutical industry includes CEO, COO and Clinical Advisor at SDS Life Science (2017-2021), Clinical- and Global Project Manager and Scientist in different positions at AstraZeneca R&D (2001 -2012). He brings almost 20 years of experience from drug development and project management.
Ph.D. Pharmacologist with 30 years’ of experience from Astra/AstraZeneca
Preclinical project leader for Losec, the first PPI on the market
Preclinical project leader for Nexium including clinical, marketing
and regulatory support
Discovery project leader on the P-CAB program bringing linaprazan through the phase II studies
Education and professional experience: Maria holds a BSc in Business Administration and Economics from Stockholm University. She was formerly the CFO of Sedana Medical Group (2017-2021) and Managing Director at Cross Pharma AB (2015–2016). Maria has also extensive experience from leading positions within finance for the past 20 years within Medivir, Biovitrum, Bristol Myers Squibb and Ericsson.
Other current engagements: Board Member in her own consultant company FAYSIT – Finance At Your Service In Tyresö AB and Advisory board member in Ugglapraktiken AB.
Ph.D in Pharmacology. More than 30 years in drug discovery and development from Pharmacia and Quintiles
Over the last 15 years, she has been on the Board of many life Science companies, private, governmentally owned and publicly listed in Norway, UK and Sweden
Currently active as Chairman of InDex Pharmaceuticals and BioArctic and member of the Board of Swedish Match and InDex Diagnostics. CEO and Board member of Rolfsen Consulting AB. Partner in Serendipity Partners.
More than 12 years experience from drug development and medical affairs within the pharmaceutical industry
He has held a broad a spectrum of positions within clinical development, pharmacovigilance, quality assurance and medical affairs at Pfizer, Ipsen, Shire and Novartis
Currently heading the Nordic medical affairs business for gene therapy at Novartis within rare ophthalmology. Anders holds a
master’s degree in medical sciences and clinical drug development from Uppsala University
Plan 8, Trappa F
111 22 Stockholm
Copyright © All Rights Reserved